[VIRTUAL] ASN51, an Orally Bioavailable Small-Molecule O-Glcnacase Inhibitor, Has Both Immediate and Disease Modifying Benefits in Preclinical Models of Parkinson’s Disease and Epilepsy

ASN51 - Asceneuron

https://2021.myana.org/sites/default/files/images/2021/2021_publication_final_-_oct_8_embargo_0.pdf

Bruno Permanne, PhD; Ryan Schubert, MD; Astrid Sand, MSc; Solenne Ousson, MSc; Maud Neny, MSc; Jennifer Hantson, MSc; Christoph Wiessner, PhD; Anna Quattropani, PhD; Dirk Beher, PhD

Oct 21, 2021